Collectively, our findings support an oncogenic role of DLGAP1-AS2 in GC progression and suggest that DLGAP1-AS2/Six3/Wnt1/β-catenin signaling axis may be a potential target for diagnosis and treatment of GC. This evidence concerns the gene WNT1 and gastric cancer.